CS
APRE icon

Candriam SCA’s Aprea Therapeutics APRE Stock Holding History

Candriam SCA’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-18,116
Closed -$1.71M – 893
2021
Q1 		$1.71M Sell
18,116
-1
-0% -$117 0.01% 544
2020
Q4 		$1.78M Buy
18,117
+6,424
+55% +$3.05M 0.01% 556
2020
Q3 		$5.63M Buy
11,693
+5,154
+79% +$2.88M 0.05% 332
2020
Q2 		$5.07M Buy
+6,539
New +$4.29M 0.05% 332

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Candriam SCA's APRE Position: Q2 2021 in Review

Candriam SCA sold out of Aprea Therapeutics (APRE) in Q2 2021, closing a stake of 18,116 shares — an estimated $1.71M sold.

Candriam SCA first reported a position in APRE in Q2 2020 and held it in 4 quarters. The position peaked at $5.63M in Q3 2020. 50 funds tracked by Wall St. Rank hold APRE as of Q2 2021.

  • Candriam SCA reported no remaining Aprea Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Candriam SCA sold 18,116 Aprea Therapeutics shares in Q2 2021, an estimated $1.71M.
  • Candriam SCA first reported a position in Aprea Therapeutics in Q2 2020 and held it in 4 quarters.
  • Candriam SCA's Aprea Therapeutics position peaked at $5.63M in Q3 2020.
  • 50 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2021.

Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.